​
​

Kymera Therapeutics Ownership | Who Owns Kymera Therapeutics?

OverviewForecastRevenueFinancialsChartTranscripts

Kymera Therapeutics Ownership Summary

Kymera Therapeutics is owned by 95.19% institutional investors, 1.27% insiders, and 3.53% retail investors. Price t rowe associates inc /md/ is the largest institutional shareholder, holding 9.03% of KYMR shares. T. Rowe Price New Horizons is the top mutual fund, with 4.86% of its assets in Kymera Therapeutics shares.

KYMR Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockKymera Therapeutics95.19%1.27%3.53%
SectorHealthcare Stocks 47.06%8.01%44.93%
IndustryBiotech Stocks 44.97%7.82%47.21%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Price t rowe associates inc /md/6.39M9.03%$190.76M
Baker bros. advisors lp6.00M8.47%$178.98M
Atlas venture life science advisors5.35M7.56%$159.71M
Bvf inc/il5.16M7.29%$154.08M
Fmr4.83M6.82%$144.08M
Vanguard group4.82M6.81%$143.95M
Wellington management group llp4.31M6.09%$128.64M
Blackrock4.16M5.87%$124.04M
Avoro capital advisors3.89M5.50%$116.08M
Artal group3.01M4.25%$89.72M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Atlas venture life science advisors5.35M16.82%$159.71M
Aquilo capital management328.74K9.46%$9.81M
Bvf inc/il5.16M4.32%$154.08M
Redmile group1.58M2.85%$47.14M
Deer management415.89K2.55%$12.41M
Artal group3.01M2.29%$89.72M
Baker bros. advisors lp6.00M2.29%$178.98M
Avoro capital advisors3.89M1.55%$116.08M
Deep track capital, lp1.50M1.34%$44.77M
Propel bio management56.36K1.09%$1.68M

Top Buyers

HolderShares% AssetsChange
Blackrock4.16M0.00%499.77K
Fmr4.83M0.01%462.43K
Eventide asset management462.10K0.24%442.32K
Ubs asset management americas433.57K0.00%253.63K
Deep track capital, lp1.50M1.34%237.75K

Top Sellers

HolderShares% AssetsChange
State street1.91M0.00%-761.83K
Jpmorgan chase44.94K0.00%-410.99K
Rock springs capital management lp1.16M1.05%-358.26K
Barclays49.09K0.00%-270.81K
Citigroup19.59K0.00%-201.32K

New Positions

HolderShares% AssetsChangeValue
Driehaus capital management223.41K0.06%223.41K$6.67M
Norges bank117.88K0.00%117.88K$3.52M
Capital fund management29.95K0.00%29.95K$894.07K
Mirae asset global etfs24.57K0.00%24.57K$734.68K
Corebridge financial23.93K0.00%23.93K$714.34K

Sold Out

HolderChange
Financial gravity asset management-2.00
Riggs asset managment-7.00
Nelson, van denburg & campbell wealth management group-8.00
Continuum advisory-13.00
Innealta capital-44.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 2024155-4.32%67,367,8330.44%950.72%86-14.85%4711.90%
Mar 31, 202416220.00%67,073,03411.04%1141.07%10148.53%42-17.65%
Dec 31, 202313510.66%60,406,7775.38%1031.07%6811.48%5145.71%
Sep 30, 2023122-6.87%57,323,132-1.85%980.98%61-8.96%356.06%
Jun 30, 20231310.77%58,403,8532.76%1001.05%678.06%33-21.43%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
T. Rowe Price New Horizons3.14M4.86%-9.90K
US Small-Cap Growth II Equity Comp3.14M4.86%161.32K
Fidelity Growth Compy Commingled Pl S2.25M3.47%12.35K
Fidelity Growth Compy Commingled Pl O2.24M3.46%52.60K
Vanguard Health Care Inv1.83M2.82%378.94K
Fidelity Growth Company Fund1.65M2.55%-3.50K
Vanguard Total Stock Mkt Idx Inv1.53M2.37%-9.61K
Vanguard Small Cap Index1.21M1.87%2.35K
T. Rowe Price Health Sciences1.20M1.85%-11.65K
iShares Russell 2000 ETF1.15M1.77%-2.58K

Recent Insider Transactions

DateNameRoleActivityValue
Sep 17, 2024Esposito Pamela-Sell$348.58K
Sep 17, 2024Esposito Pamela-Sell$303.18K
Aug 26, 2024Albers Jeffrey W.-Sell$245.51K
Aug 20, 2024BVF PARTNERS L P/IL See Remarks and FootnotesBuy$15.67
Aug 20, 2024BVF PARTNERS L P/IL See Remarks and FootnotesBuy$20.15

Insider Transactions Trends

DateBuySell
2024 Q3516
2024 Q2-9
2024 Q1349
2023 Q46-
2023 Q3--

KYMR Ownership FAQ

Who Owns Kymera Therapeutics?

Kymera Therapeutics shareholders are primarily institutional investors at 95.19%, followed by 1.27% insiders and 3.54% retail investors. The average institutional ownership in Kymera Therapeutics's industry, Biotech Stocks , is 44.97%, which Kymera Therapeutics exceeds.

Who owns the most shares of Kymera Therapeutics?

Kymera Therapeutics’s largest shareholders are Price t rowe associates inc /md/ (6.39M shares, 9.03%), Baker bros. advisors lp (6M shares, 8.47%), and Atlas venture life science advisors (5.35M shares, 7.56%). Together, they hold 25.06% of Kymera Therapeutics’s total shares outstanding.

Does Blackrock own Kymera Therapeutics?

Yes, BlackRock owns 5.87% of Kymera Therapeutics, totaling 4.16M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 124.04M$. In the last quarter, BlackRock increased its holdings by 499.77K shares, a 13.67% change.

Who is Kymera Therapeutics’s biggest shareholder by percentage of total assets invested?

Atlas venture life science advisors is Kymera Therapeutics’s biggest shareholder by percentage of total assets invested, with 16.82% of its assets in 5.35M Kymera Therapeutics shares, valued at 159.71M$.

Who is the top mutual fund holder of Kymera Therapeutics shares?

T. Rowe Price New Horizons is the top mutual fund holder of Kymera Therapeutics shares, with 4.86% of its total shares outstanding invested in 3.14M Kymera Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools